← Pharmacy curriculum
Module 1068 lessonsOriginal NaS synthesis of reproductive and urinary medicinal chemistry, RxPrep scope, NIH PubChem structures, and current US product labeling

Genitourinary Medicinal Chemistry

Read molecular structure, stereochemistry, ionization, metabolism, route, and formulation across reproductive and urinary medicines, then keep every prediction within its clinical evidence boundary.

01

Recognize steroidal and nonsteroidal pharmacophores without equating shared shape with clinical interchangeability.

02

Map administered parents, prodrugs, active metabolites, salts, and route-specific exposure.

03

Compare 5 alpha reductase, PDE5, muscarinic, beta 3, and alpha 1 drug design.

04

Use ionization, stereochemistry, metabolism, and formulation to generate testable pharmacologic predictions.

05

Verify structure based predictions against current labeling, evidence, organ function, and patient goals.

106.01

Lesson

Steroid Architecture and Receptor Recognition

A shared fused-ring nucleus becomes many different signals through oxidation, substitution, stereochemistry, receptor conformation, and delivery.

What to learn
  • Fused-ring nucleus
  • Stereochemistry
  • Intracellular receptors
  • Route-dependent exposure
Molecular foundationOne nucleus, several biologic signals
01ShapeFused rings

Rigid geometry positions every substituent

02TuneFunctional groups

Hydroxyls, carbonyls, and side chains change recognition

03OrientStereochemistry

Three-dimensional identity controls receptor fit

04DeliverRoute

First pass, local exposure, and depot release reshape the signal

Begin with the common framework

Estrogens, progestogens, and androgens share a compact fused-ring system. Carbon count, ring unsaturation, hydroxyl and carbonyl placement, side chains, and stereochemistry determine how the framework is recognized and metabolized.

Read the molecule in three dimensions

Receptor pockets distinguish spatial orientation. An epimer or enantiomer can preserve formula while changing hydrogen-bond geometry, hydrophobic contact, metabolic access, and biologic activity.

Follow receptor conformation into tissue

Steroid receptors are intracellular transcription factors. Ligand binding changes receptor shape and coregulator recruitment, so the same ligand can produce different effects across tissues with different receptor and coregulator environments.

Treat route as chemical context

Oral, transdermal, vaginal, injectable, and intrauterine products create different hepatic first-pass exposure, concentration profiles, local delivery, and active-metabolite patterns. Route cannot be separated from the medicinal chemistry of the product.

Quick check

0 of 1 answered
01What is the safest interpretation of two medicines that share a steroid nucleus?
Answer every question to submit.
106.02

Lesson

Estrogen Design and Tissue Selectivity

Ethynyl substitution, esterification, particle design, mixtures, and selective receptor modulation solve different delivery and tissue-response problems.

What to learn
  • Ethinyl estradiol
  • Estradiol esters
  • Micronized and conjugated products
  • Selective receptor modulation
Estrogen designModify delivery without erasing biology
01Persist17 alpha ethynyl

Slows rapid C17 oxidation for oral exposure

02ReleaseEstradiol ester

Lipophilic depot undergoes hydrolysis

03FormulateParticles and mixtures

Micronization and composition define the product

04SelectReceptor conformation

Coregulator context creates tissue-dependent response

Protect oral activity

Estradiol is vulnerable to rapid first-pass metabolism. The 17 alpha ethynyl group in ethinyl estradiol slows oxidation at C17 and supports oral exposure, but the same systemic and hepatic persistence requires product-specific safety assessment.

Build a depot with an ester

Esterifying the C17 hydroxyl increases lipophilicity and can slow release from an injection vehicle. Hydrolysis then liberates estradiol. The ester is a delivery modification, and milligram strengths across esters are not direct active-hormone equivalents.

Name the actual product

Micronized estradiol changes particle behavior, while conjugated estrogen products contain defined mixtures or salts rather than one generic estrogen molecule. Active ingredient, dosage form, route, and labeled potency must all be read directly.

Make selectivity tissue contextual

SERMs stabilize receptor conformations that recruit different coregulators across bone, breast, endometrium, and liver. They are neither universal estrogen agonists nor universal antagonists, and tissue claims require clinical evidence.

Quick check

0 of 1 answered
01What is the main medicinal chemistry role of the 17 alpha ethynyl group in ethinyl estradiol?
Answer every question to submit.
106.03

Lesson

Progestin Families and Active Species

Progesterone-like, testosterone-derived, and spironolactone-related scaffolds produce distinct receptor, metabolic, and delivery profiles.

What to learn
  • Structural ancestry
  • Levonorgestrel stereochemistry
  • Desogestrel activation
  • Drospirenone profile
Progestin mapFollow ancestry, active species, and receptor profile
01ClassifyStructural family

Progesterone, testosterone, or spironolactone ancestry

02ResolveStereochemical identity

Levonorgestrel preserves the active configuration

03ActivateDesogestrel

Metabolism forms active etonogestrel

04DifferentiateDrospirenone

Distinct antiandrogenic and antimineralocorticoid activity

Use families as a starting map

Progestins can be progesterone-like, testosterone-derived, or related to spironolactone. Substitutions tune progestogenic potency, androgenic tendency, mineralocorticoid activity, metabolism, and half-life, but no family label proves a clinical outcome.

Preserve levonorgestrel identity

Levonorgestrel is the active levorotatory enantiomer related to racemic norgestrel. Stereochemical composition matters when comparing molecule names and strengths.

Follow desogestrel to etonogestrel

Oral desogestrel is converted to active etonogestrel. Etonogestrel is also delivered directly by implant and vaginal products, so the same active species can arise from metabolic activation or from direct controlled release.

Interpret drospirenone precisely

Drospirenone is structurally related to spironolactone and has progestogenic, antiandrogenic, and antimineralocorticoid activity. This explains potassium-related precautions in selected settings but does not make it a therapeutic diuretic.

Quick check

0 of 1 answered
01Which statement correctly connects desogestrel and etonogestrel?
Answer every question to submit.
106.04

Lesson

5 Alpha Reductase Inhibitor Chemistry

Steroid-like enzyme inhibitors reduce DHT formation through distinct isoenzyme and persistence profiles, producing gradual tissue effects rather than immediate outlet relaxation.

What to learn
  • Enzyme transition state
  • Finasteride
  • Dutasteride
  • DHT pathway
Androgen pathwayInterrupt ligand formation before receptor signaling
01SubstrateTestosterone

5 alpha reductase normally forms DHT

02InhibitFinasteride

Preferential type 2 enzyme inhibition

03BroadenDutasteride

Type 1 and type 2 inhibition with long persistence

04RemodelTissue response

Reduced DHT gradually changes prostate and follicle biology

Mimic the enzyme substrate

Finasteride and dutasteride use steroid-like geometry to engage 5 alpha reductase and interrupt testosterone reduction. Tight enzyme interactions reduce DHT formation, but the medicines do not directly occupy the androgen receptor.

Define finasteride by product

Finasteride preferentially inhibits type 2 enzyme. Current products use different strengths and evidence for BPH and androgenetic alopecia, so the active ingredient alone does not justify interchanging indication or dose.

Account for dutasteride persistence

Dutasteride inhibits type 1 and type 2 enzyme and has a long terminal half-life. Lipophilicity, CYP3A handling, accumulation, and slow washout matter when reviewing interactions, adverse effects, and discontinuation.

Connect chemistry to the clinical timeline

DHT reduction gradually changes androgen-driven prostate tissue and hair-follicle signaling. Rapid symptom relief belongs to other mechanisms, while PSA interpretation and reproductive counseling require deliberate longitudinal follow-up.

Quick check

0 of 1 answered
01Why does a 5 alpha reductase inhibitor not provide the same rapid effect as an alpha blocker?
Answer every question to submit.
106.05

Lesson

PDE5 Inhibitor Recognition and Persistence

Different heterocyclic scaffolds preserve cGMP signaling with product-specific selectivity, stereochemistry, metabolism, duration, and interaction windows.

What to learn
  • Catalytic-pocket recognition
  • Sildenafil and vardenafil
  • Tadalafil
  • cGMP interaction convergence
Second-messenger controlPreserve cGMP, then respect the interaction window
01InitiateNitric oxide

Upstream signaling activates guanylate cyclase

02SignalcGMP

Smooth-muscle relaxation follows messenger accumulation

03PreservePDE5 inhibitor

Catalytic-pocket binding slows cGMP breakdown

04AvoidNitrate convergence

More production plus less breakdown can collapse pressure

Preserve the second messenger

PDE5 inhibitors occupy the enzyme catalytic pocket and slow cGMP hydrolysis. They preserve a signal produced after nitric oxide activation and do not independently create the initiating physiologic stimulus.

Compare related scaffolds carefully

Sildenafil and vardenafil use related heterocyclic designs, but substituents tune potency, PDE selectivity, food effects, electrophysiologic considerations, and pharmacokinetics. Shared class does not erase product instructions.

Recognize tadalafil as structurally distinct

Tadalafil uses a rigid fused heterocyclic scaffold with defined stereochemistry and prolonged exposure. CYP3A, renal and hepatic function, daily versus as-needed use, and a longer interaction window remain central.

See the cGMP collision

Nitrates and guanylate cyclase stimulators increase cGMP production while PDE5 inhibitors reduce cGMP breakdown. Their pathway convergence can cause profound hypotension and is a product-label contraindication.

Quick check

0 of 1 answered
01Why are nitrates contraindicated with PDE5 inhibitors?
Answer every question to submit.
106.06

Lesson

Bladder Antimuscarinic Chemistry

Charge state, hydrophobicity, metabolism, transport, and delivery systems shape bladder exposure, anticholinergic burden, and CNS risk.

What to learn
  • Muscarinic pharmacophore
  • Tertiary and quaternary amines
  • Oxybutynin metabolism
  • Trospium distribution
Distribution logicCharge, metabolism, and route shape antimuscarinic burden
01BindCationic center

Hydrophobic groups complete muscarinic recognition

02PartitionTertiary amine

A partly uncharged fraction can cross membranes

03RestrictQuaternary charge

Trospium has limited passive diffusion

04EngineerOxybutynin route

Release and first pass alter parent and active metabolite exposure

Recognize the distributed pharmacophore

A cationic center and hydrophobic domains at an appropriate spacing support muscarinic binding. Flexibility, stereochemistry, receptor affinity, and active metabolites make individual agents distinct.

Read charge at physiologic pH

Tertiary amines can exist partly uncharged and cross membranes more readily. Quaternary ammonium compounds remain charged. Lipophilicity, transporters, protein binding, dose, and patient physiology still contribute to CNS exposure.

Follow oxybutynin through first pass

CYP3A metabolism forms active N-desethyloxybutynin, which contributes to anticholinergic effects. Immediate release, extended release, and transdermal delivery produce different parent and metabolite profiles.

Use trospium as a qualified prediction

Trospium is permanently charged and has limited passive membrane diffusion with substantial renal handling. Lower expected CNS access does not remove retention, gastrointestinal, ocular, or cognitive monitoring in vulnerable patients.

Quick check

0 of 1 answered
01What most directly distinguishes trospium from many tertiary-amine bladder antimuscarinics?
Answer every question to submit.
106.07

Lesson

Adrenergic Chemistry in Bladder and Outlet Care

Beta 3 agonists and alpha 1 antagonists solve different bladder-storage and outlet-tone problems with distinct scaffolds and interaction profiles.

What to learn
  • Mirabegron
  • Vibegron
  • Alpha blocker diversity
  • Functional-group interpretation
Two autonomic targetsStore urine or reduce outlet tone through distinct chemistry
01StoreMirabegron

Noncatechol beta 3 activation relaxes detrusor

02SeparateVibegron

Shared receptor, distinct disposition and interactions

03OpenAlpha 1 blockade

Scaffold and subtype preference tune outlet relaxation

04InterpretFunctional groups

One shared motif does not prove cross-allergy

Relax storage through beta 3

Mirabegron is a noncatechol oral beta 3 agonist that relaxes detrusor muscle during storage. Its structure supports persistence, but CYP2D6 inhibition, blood pressure, organ function, and retention risk remain clinically relevant.

Keep vibegron product specific

Vibegron reaches the same receptor class through a chemically distinct scaffold and does not inherit every mirabegron interaction by analogy. Current labeling, including digoxin and administration information, governs use.

Compare alpha blocker scaffolds

Quinazoline and other alpha 1 antagonist designs differ in subtype preference, metabolism, lipophilicity, orthostasis, and ejaculation effects. Uroselectivity shifts a profile but does not create prostate-only exposure.

Do not overread one functional group

A sulfonamide-related motif in tamsulosin does not make it a sulfonamide antibiotic. Allergy assessment requires the prior reaction, complete scaffold, product information, and available alternatives rather than a blanket motif rule.

Quick check

0 of 1 answered
01Why should vibegron not automatically inherit mirabegron's CYP2D6 interaction profile?
Answer every question to submit.
106.08

Lesson

Product Engineering and Evidence Boundaries

Release systems, salts, local devices, active moieties, and clinical evidence complete the path from molecular structure to a usable medicine.

What to learn
  • Extended release
  • Local delivery
  • Salt conventions
  • Evidence boundary
Product realityThe molecule is only one layer of the medicine
01DefineActive species

Parent, prodrug, metabolite, salt, and stereochemistry

02ControlDelivery system

Matrix, membrane, depot, device, and local route

03VerifyRegulatory label

Strength, manipulation, indication, dose, and interactions

04DecidePatient context

Organ function, evidence, preferences, and monitoring

Protect release-system integrity

Matrix, membrane, and osmotic systems control input rate. Crushing, chewing, splitting, or opening can defeat that control, so dosage-form manipulation follows exact manufacturer instructions rather than molecule-level intuition.

Map local and systemic exposure

Vaginal rings, intrauterine systems, transdermal patches, urethral pellets, and intracavernosal injections target anatomy differently but can still produce systemic exposure and class effects.

Read salts and strengths correctly

Salt formation can improve stability, crystallinity, or dissolution. The regulatory label defines whether strength is expressed as salt or active moiety, and unsupported molecular-weight conversion creates error rather than precision.

Stop where structure stops

Structure can predict charge, likely metabolism, target recognition, and formulation challenges. It cannot by itself establish indication, dose, effectiveness, pregnancy safety, or suitability for an individual patient.

Quick check

0 of 1 answered
01What is the correct final step after making a structure based pharmacologic prediction?
Answer every question to submit.

Module test

Check the connections.

Each attempt draws 10 questions from the complete 128 question bank.

128 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

References

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. NIH PubChem. Ethinylestradiol
  2. NIH PubChem. Levonorgestrel
  3. NIH PubChem. Drospirenone
  4. NIH PubChem. Finasteride
  5. NIH PubChem. Dutasteride
  6. NIH PubChem. Tadalafil
  7. NIH PubChem. Oxybutynin
  8. DailyMed. Finasteride tablets
  9. DailyMed. Tadalafil tablets
  10. DailyMed. Oxybutynin extended release
  11. DailyMed. Mirabegron extended release
PharmacyOpen tools